Vicplas International Ltd, a SGX Mainboard-listed manufacturer of medical devices and piping systems, announced a 9.4% year-on-year increase in net profit to S$245,000 for the first half of its financial year ended 31 January 2025 (“1H2025”). Revenue rose 6.4% to S$54.3 million, driven by stronger performance in its medical devices segment, though operational expansions and cost pressures tempered margins.
Financial Performance
The medical devices segment saw revenue climb 10.5% to S$35.0 million, fueled by post-pandemic inventory restocking among key customers. However, the segment’s results remained negative at S$0.4 million due to startup costs for its new Mexico plant and expansion expenses at its Changzhou facility in China. In contrast, the pipes and pipe fittings segment reported a marginal 0.4% revenue dip to S$19.3 million, as the company prioritized credit risk management amid competitive pressures in Singapore’s construction sector. Group-wide profit before tax surged 82.3% to S$0.5 million, while adjusted EBITDA improved 9.5% to S$4.4 million.
Mr. Walter Tarca, Group CEO of Vicplas, commented: “While our medical devices segment benefits from recovering demand, we are mindful of inflationary and interest rate headwinds. Our expansions in Mexico and China position us for long-term growth, but prudent cost management remains critical.”
Outlook
Vicplas continues to invest in global capacity, with its Mexico plant set to contribute revenue in the second half of FY2025. The “In China for China” strategy also gained traction, though near-term profitability will be constrained by ramp-up costs. Meanwhile, the pipes segment is leveraging its four Singapore Green Mark certifications to align with sustainable construction trends.
The Group expects revenue growth to continue, supported by medical device commercialization and Singapore’s robust construction activity. However, global macroeconomic uncertainties and fixed-cost expansions warrant cautious optimism.
